Literature DB >> 15553104

A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography.

Durairaj Chandrasekar1, Sistla Ramakrishna, Prakash V Diwan.   

Abstract

A simple and sensitive method for the determination of ondansetron (CAS 116002-70-1) in human plasma was developed using high-pressure liquid chromatography (HPLC). The procedure involves extraction of human plasma with tertiary butyl methyl ether containing 2 mol/l sodium hydroxide, followed by reversed-phase HPLC using a LiChrospher 100 RP-18e 5 microm column and UV detection at 305 nm. The retention times of ondansetron and internal standard (propranolol hydrochloride, CAS 318-98-9) were 9.38 and 13.40 min, respectively. The calibration curves were linear over the range of 10 ng/ml (lower limit of quantitation, LOQ) and 380 ng/ml for ondansetron. The intra- and inter-assay coefficients of variation for all the criteria of validation were less than 15% over the linearity range. Ondansetron was stable upon storage in human plasma. The sensitivity and precision of the method were within the accepted limits (< 15 %) throughout the validation period. The present method is useful for determination of plasma concentrations of ondansetron during human pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15553104     DOI: 10.1055/s-0031-1297017

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome.

Authors:  M H Elkomy; P Sultan; B Carvalho; G Peltz; M Wu; C Clavijo; J L Galinkin; D R Drover
Journal:  Clin Pharmacol Ther       Date:  2014-12-04       Impact factor: 6.875

2.  Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers.

Authors:  Yubing Zhu; Qian Zhang; Jianjun Zou; Meng Wan; Zheng Zhao; Junrong Zhu
Journal:  Drug Des Devel Ther       Date:  2015-08-12       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.